NAD+ Benefits: What the Evidence Shows

The short answer

NAD+ is a coenzyme found in every cell, required for turning food into ATP and for the enzymes that repair DNA and regulate metabolism. Its levels fall with age, and that decline is the reason it became one of the most researched targets in longevity science. Two things are well established: the precursors NR and NMN reliably raise NAD+ in human blood, and injected NAD+ delivers the molecule directly. Two things are not: whether raising NAD+ produces meaningful benefits in healthy people, and whether any route does so over years. The trials that exist are short and small, and their results are mixed, with a few positive metabolic and physical-performance signals against a larger number of null findings. NAD+ swallowed as NAD+ is not effective; that is the one part of this field the marketing consistently gets wrong.

What NAD+ does

Nicotinamide adenine dinucleotide is an electron carrier. In its oxidized form, NAD+, it accepts electrons from the breakdown of glucose and fat and becomes NADH; NADH then hands those electrons to the mitochondrial electron transport chain, where they drive the production of ATP. Without NAD+ cycling between those two forms, mitochondrial energy production stops. That role alone would make it essential, and it is the older, textbook half of the story.

The half that made NAD+ a longevity target is that it is also a substrate, consumed rather than recycled, by three families of enzymes. The sirtuins (SIRT1 through SIRT7) use NAD+ to regulate metabolism, stress responses and mitochondrial biogenesis. The PARPs use it to repair damaged DNA. And CD38 and related enzymes use it for calcium signaling and, it turns out, waste a great deal of it. Because these enzymes consume NAD+, cellular levels reflect a balance between synthesis and consumption, and anything that shifts the balance changes how much is available for energy metabolism and repair.

Why it declines with age

NAD+ falls with age in most tissues studied, in humans as well as animals, and the drop is not primarily a failure of synthesis. The dominant explanation is increased consumption: CD38 expression rises with age, driven in part by chronic low-grade inflammation, and CD38 is a wasteful NAD+ consumer that degrades far more of the molecule than it needs for signaling. PARP activation in response to accumulating DNA damage adds to the drain. The salvage pathway that recycles nicotinamide back into NAD+, through the rate-limiting enzyme NAMPT, also becomes less efficient. The result is less NAD+ for the sirtuins and for mitochondria, which is the mechanistic link to the reduced mitochondrial function seen in aging tissue.

⚠ CLAIM (wellness): NAD+ levels decline with age in human tissues, and this decline is associated with reduced mitochondrial function and increased activity of NAD+-consuming enzymes such as CD38. Whether restoring NAD+ reverses age-related decline in humans has not been demonstrated. Basis: Covarrubias 2021 Nat Rev Mol Cell Biol; Rajman 2018 Cell Metab. Lane: educational.

The routes: which ones actually deliver NAD+

This is the part most people, and most product labels, get wrong, so it deserves its own table.

Route	What it delivers	Status of the human evidence
Oral NAD+ (capsule, powder)	Mostly nicotinamide, after gut and liver breakdown	Not an effective route for NAD+ itself
Liposomal oral NAD+	Unclear	Being researched; absorption not established
Nasal spray, transdermal patch	Unknown	No human data
IV infusion, subcutaneous injection	NAD+ itself, directly	Established clinical routes; pharmacokinetics published; no outcome trials
NR (nicotinamide riboside), oral	A precursor cells convert to NAD+	Reliably raises blood NAD+; multiple RCTs
NMN (nicotinamide mononucleotide), oral	A precursor one step closer to NAD+	Reliably raises blood NAD+; several RCTs

Taken by mouth, NAD+ is dismantled in the intestine and liver before it reaches the bloodstream intact, and cells do not readily import whole NAD+ from outside anyway. Liposomal oral NAD+ is being researched as a way around this and the evidence is unclear. IV and subcutaneous NAD+ are the established, researched routes for delivering the molecule itself, with decades of clinical use and a published pharmacokinetic study, though no controlled outcome trial; they are clinical procedures with their own side effect profile. The precursors are what make convenient oral dosing possible: NR and NMN are small enough to be absorbed and cells rebuild NAD+ from them. The alternative routes are examined in NAD+ nasal spray, patches and liposomal NAD+.

NR: the most-studied precursor

Nicotinamide riboside was the first precursor shown to be orally bioavailable in humans, in a 2016 pharmacokinetic study, and it has the largest trial base. The pattern across those trials is consistent and a little deflating. Martens and colleagues gave 1 g a day for six weeks to middle-aged and older adults and found blood NAD+ rose by about 60 percent, with good tolerability and a trend toward lower blood pressure that did not reach significance. Dollerup gave 2 g a day for twelve weeks to obese men and found no improvement in insulin sensitivity, energy expenditure or body composition. Remie gave 1 g a day for six weeks and found no metabolic benefit. Elhassan gave 1 g a day for three weeks to older men and found the muscle NAD+ metabolome rose and inflammatory markers fell, without a change in mitochondrial function. The NADPARK trial gave 1 g a day for thirty days to people with Parkinson’s disease and showed, using brain spectroscopy, that NAD+ in the brain rose, with a shift in metabolic gene expression and a mild clinical signal that a larger trial is now testing. The trial-by-trial detail, the forms and salts, and what to check on a label are in nicotinamide riboside benefits.

⚠ CLAIM (wellness): Oral nicotinamide riboside at 1 to 2 g per day reliably raises blood NAD+ in human trials and has been shown to raise brain NAD+ in Parkinson’s disease. Trials in healthy and obese adults have generally not found improvements in insulin sensitivity, mitochondrial function or body composition. Basis: Martens 2018; Dollerup 2018; Remie 2020; Elhassan 2019; Brakedal 2022. Lane: educational.

NMN: closer to NAD+, with a few positive signals

NMN sits one step downstream of NR in the salvage pathway, and its trial results are modestly more encouraging, though the trials are small. Yoshino gave 250 mg a day for ten weeks to postmenopausal women with prediabetes and found skeletal muscle insulin sensitivity improved by about a quarter, without a change in blood NAD+ or body composition. Igarashi gave 250 mg a day for twelve weeks to older men and reported small gains in gait speed and grip strength. Yi ran the only dose-ranging study, 300, 600 or 900 mg a day for sixty days, and found blood NAD+ rose with dose and six-minute walk distance improved, with 600 mg performing about as well as 900. Okabe confirmed safety at 250 mg for twelve weeks with no notable adverse events.

How NMN gets into cells remains disputed. The Imai laboratory reported a dedicated transporter, Slc12a8, that moves NMN intact across the gut wall. Brenner’s group argued the evidence did not support that and that NMN is first converted to NR outside the cell. If Brenner is right, NMN is essentially a more expensive way to deliver NR; if Imai is right, it may have a route of its own. The dispute is unresolved and bears on which formulation claims are credible. Choosing between them, and choosing a product, is covered in NMN vs NAD+ vs NR and best NMN supplement. For the cross-precursor buying question, including why a capsule labelled NAD+ cannot do what its name implies, see best NAD+ supplement. NMN’s regulatory status in the United States was contested from late 2022 until September 2025, when the FDA reversed its position and confirmed it can be sold as a dietary supplement; that was a legal decision, not a safety finding.

⚠ CLAIM (wellness): Oral NMN at 250 to 900 mg per day raises blood NAD+ and, in individual small trials, improved muscle insulin sensitivity in prediabetic women and walking distance in middle-aged adults. These findings have not been replicated at scale and do not show effects on aging or disease outcomes. Basis: Yoshino 2021 Science; Igarashi 2022; Yi 2023. Lane: educational.

What the evidence adds up to

The biochemistry is settled and the outcomes are not. Every precursor trial that measured it found NAD+ rose. What did not follow, in most trials, was a change in the things people take these supplements for. The positive findings are real but scattered: insulin sensitivity in one NMN trial, walking distance in another, brain NAD+ in one NR trial, inflammatory markers in another. The nulls are at least as numerous and include the largest and longest studies. That pattern is consistent with two readings. Either raising NAD+ in already-healthy people has little room to improve anything, and benefits will show up only where NAD+ is genuinely depleted, in disease or advanced age; or the trials are too short to catch effects that accrue slowly. Both are being tested. Neither justifies the confidence in the marketing.

What raises NAD+ without a supplement is worth stating plainly, because it is better evidenced than the supplements are. Aerobic exercise increases NAMPT and NAD+ turnover in muscle and improves every outcome the precursors are marketed for. Caloric restriction and time-restricted eating raise NAD+ through the same pathway. Sleep and circadian regularity matter because NAD+ synthesis is under clock control, with NAMPT expression oscillating daily; disrupting the clock lowers the oscillation. None of these costs anything.

Safety and what to watch for

NR and NMN are well tolerated in every trial to date, at doses well above what most products supply, for up to a few months. The common side effects are nausea, flushing and stomach upset, and community reports add sleep disruption with evening dosing. The unresolved questions are longer-term and mechanistic: whether clearing the nicotinamide load through methylation matters over years, and what raising NAD+ does to an existing tumor, where preclinical evidence contradicts itself and no human data exist. Injected NAD+ has its own profile of rate-dependent infusion reactions. All of it is laid out in NAD+ supplement side effects. Anyone with a current or recent cancer diagnosis should ask an oncologist before starting any NAD+ product.

On product quality: NMN degrades to nicotinamide in heat and humidity, and independent testing has repeatedly found marketplace NMN products containing far less than declared. NR is more stable but not immune. For either, a batch-specific certificate of analysis from an independent laboratory showing purity, identity and contaminant testing is the minimum standard. A brand’s reputation is not a substitute.

How to think about it

NAD+ precursors do what they say at the biochemical level, and the field has done the honest thing by running trials rather than resting on the mechanism. Those trials say the effect on how you feel and how you age is small, uncertain, or not yet visible. If you try them, use a verified product at a dose in the tested range, dose in the morning, and set expectations accordingly. If you want the strongest evidence-based way to support NAD+ metabolism, it is still exercise. A broader view of the compounds that hold up is in best supplements for mitochondrial health, and the reasons people give up on NMN are in why people stop taking NMN.

Educational information only, not medical advice, and not evaluated by the FDA. NAD+, NR and NMN are not treatments for any disease. Long-term safety beyond a few months has not been established. Injected and infused NAD+ are clinical procedures and are not covered here. Talk to a clinician before supplementing if you have a current or previous cancer diagnosis, take prescription medication, or are pregnant or breastfeeding.